STHENOS · COMB157G3301
Public neurological clinical research study information. Check the current recruitment status in the live Wix study record.
An open-label, randomized, assessor-blinded, multicenter, parallel-group, active-comparator study evaluating the efficacy and tolerability of monthly subcutaneous ofatumumab 20 mg versus physician-selected first-line disease-modifying therapy in newly diagnosed relapsing multiple sclerosis (STHENOS). EudraCT: 2020-004505-32.
Sponsor: Novartis
Phase: III
Area: Neuroimmunology